40 results about "Plasmin activity" patented technology

The invention discloses a plasmin lumbrukinase peptide dietary therapy formula suitable for rehabilitation of cardiovascular and cerebrovascular diseases, blood circulation promoting, blood stasis removing, thrombolysis, collateral dredging and microcirculation improving, and relates to the technical field of medicine and food homology dietary therapy. Soybean protein isolate and earthworm protein are used as core thrombolytic active raw materials, isomaltooligosacharide, xylitol, German Jilida collagen peptide, soybean peptide powder, Belgian imported inulin, red yeast rice and natto powder are compounded, microcrystalline cellulose and magnesium stearate are used as auxiliary materials, and probiotics / metabiotics strains such as rhamnolactobacilli JYLR-005 and the like can be selectively added. The raw materials have a synergistic effect through precise matching, plasmin and lumbrukinase peptide in earthworm protein can directly dissolve thrombus fibrin, natto powder and red yeast rice assist in lowering lipid and dissolving thrombus, multiple active peptides and prebiotics regulate intestinal microecology to improve microcirculation of the whole body, probiotics / metabiotics further strengthen the metabolic capacity of the body, no chemical medicine is added in the whole process, and the traditional Chinese medicine composition is free of toxic and side effects and free of toxic and side effects. The safety is high; the dietary therapy composition can achieve postoperative rehabilitation conditioning of cardiovascular and cerebrovascular diseases through daily consumption, effectively promote blood circulation to remove blood stasis, dissolve thrombus and dredge collaterals, improve microcirculation and relieve various discomfort caused by blood vessel clogging, raw materials are easy to obtain, compatibility is scientific, and the dietary therapy composition is suitable for large-scale production and popularization.

The invention belongs to the technical field of food, and particularly relates to application of nisin in inhibiting plasmin activity and improving quality of milk and / or dairy products. The nisin disclosed by the invention can be used for remarkably inhibiting the activity of plasmin. The nisin disclosed by the invention is a food additive allowed to be used, the INS number is 234, and the nisin is high in safety. Plasmin is a key enzyme causing deterioration of milk and milk quality, and the nisin disclosed by the invention improves the quality of milk and / or dairy products from the source by inhibiting the activity of plasmin.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and / or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.

The present application relates to a method for promoting the degradation of pathological TDP-43 protein, comprising administering to a subject a therapeutically effective amount of one or more compounds selected from components of the plasminogen activation pathway, compounds that can activate plasminogen directly or indirectly by activating upstream components of the plasminogen activation pathway, compounds that mimic the activity of plasminogen or plasmin, compounds that can upregulate the expression of plasminogen or plasminogen activators, plasminogen analogs, plasmin analogs, tPA or uPA analogs, and antagonists of fibrinolysis inhibitors. The present application also relates to agents that promote the degradation of pathological TDP-43 protein and uses thereof.

This invention discloses a multi-enzyme preparation for industrial cell dissociation, its usage method, and applications, belonging to the field of seed cell extraction technology for industrial meat culture. The invention employs a multi-enzyme preparation composed of component 1 and component 2; component 1 includes neutral protease, hyaluronidase, and elastase; component 2 includes matrix metalloproteinase, papain, and plasmin. The invention also discloses the preparation method and applications of the multi-enzyme preparation. The rational enzyme ratio and optimized treatment conditions of this invention help protect cell membrane integrity, maintain high cell activity, and significantly improve dissociation efficiency and cell recovery. The compound enzyme preparation is highly adaptable, applicable to various tissue types and dissociation requirements, and facilitates standardized and large-scale production. Combined with automated dissociation equipment, the compound enzyme preparation enables efficient and stable industrial operation, providing important technical support and broad application prospects for the cultured meat industry, tissue engineering, and cell therapy.

To provide an antigen-binding protein comprising an antigen-binding domain that binds to plasmin. Also provided are compositions comprising the antigen binding proteins, as well as uses thereof and methods of treatment comprising the same.SOLUTION: To provide antigen-binding proteins or antigen-binding fragments thereof that specifically bind to the serine protease domain of plasmin and inhibit or reduce plasmin activity via interaction with the catalytic site of the protein.SELECTED DRAWING: None

This invention discloses the application of the plasmin inhibitor NKI10 in the preparation of drugs for preventing and treating excessive inflammatory responses, belonging to the field of biomedical technology. The amino acid sequence of the plasmin inhibitor NKI10 disclosed in this invention is shown in any one of SEQ ID NO. 1 to 10. The plasmin inhibitor NKI10 can significantly inhibit the production of IL-6, IL-1β, and TNF-α in animal and cellular inflammation models. Since the plasmin inhibitor NKI10 can inhibit excessive inflammatory responses, it can be prepared for use as a drug for preventing and treating excessive inflammatory responses.

The application provides a plasmin alpha2 plasmin inhibitor complex antibody 4C1 and 2D5, the sequence of the heavy chain variable region of the antibody 4C1 is shown as SEQ ID NO:1, and the light chain variable region is shown as SEQ ID NO:2; the sequence of the heavy chain variable region of the antibody 2D5 is shown as SEQ ID NO:9, and the light chain variable region is shown as SEQ ID NO:10. The detection sensitivity of the antibody is high.

The invention discloses plasmin based on hermetia illucens and application thereof, and belongs to the technical field of biology. The plasmin based on the hermetia illucens is obtained by grinding and centrifuging larvae of the hermetia illucens in a PBS (Phosphate Buffer Solution) and extracting supernate. The invention further provides application of the plasmin based on the hermetia illucens in preparation of thrombolytic drugs. The plasmin is extracted from the hermetia illucens, and the hermetia illucens is short in breeding cycle, high in reproductive capacity, capable of being massively extracted in a short time and low in cost; the extracted plasmin has a remarkable thrombolysis effect and has a very good utilization value; the plasmin can be used for directly dissolving thrombus and degrading fibrinogen.

The invention discloses a tranexamic acid-tyrosinase inhibitor hybrid conjugate as well as a preparation method and application thereof, belongs to the technical field of cosmetics and biological medicines, and particularly relates to a tranexamic acid-tyrosinase inhibitor hybrid conjugate shown in a formula (I) and a skin composition taking the compound as an active component. According to the hybrid conjugate, tranexamic acid and a tyrosinase inhibitor are integrated into a single-structure molecule through an ester bond, so that the transdermal efficiency can be improved and the transdermal dynamic difference limitation of a traditional compound preparation can be broken through by adjusting the hydrophilic-hydrophobic balance of the compound; and plasmin activity can be inhibited through cooperation of tranexamic acid, so that melanin generation signal transmission capability and tyrosinase inhibition capability of tyrosinase inhibitor specificity are reduced, and efficient and mild multi-channel whitening and spot fading are realized. As a whitening active matter, the tranexamic acid-tyrosinase inhibitor hybrid conjugate disclosed by the invention has a great application prospect in the aspects of whitening and freckle removing effects.

The present disclosure provides an ADC comprising a plasmin cleavage site. The ADC according to the present disclosure can have a hydrophobic portion between an antibody and a plasmin cleavage site, and the hydrophobic portion includes no uncharged hydrophilic polymers such as polyethylene glycol (PEG).

The present disclosure provides compositions for hemostasis blood testing, as well as related methods, systems, kits, and sample holders. The compositions include any one or more of (a) a plurality of phospholipids, (b) a plurality of activators, (c) a blood coagulation initiator, and (d) plasmin or a precursor thereof. In some embodiments, the composition further includes one or more of (e) a buffer, (f) a sugar, (g) a protein concentration reference standard, and (h) CaCl2.

The invention relates to the technical field of in-vitro diagnosis, and discloses a plasmin-alpha 2 plasmin inhibitor compound detection kit and a preparation method and application thereof.The plasmin-alpha 2 plasmin inhibitor compound detection kit comprises a reagent M, a reagent R1, a reagent R2, a calibration product and a quality control product, and the reagent M comprises a plasmin-alpha 2 plasmin inhibitor compound antibody coated Tosyl magnetic bead suspension; the R1 reagent is a phosphate buffer solution; the reagent R2 comprises an acridinium ester labeled plasmin-alpha 2 plasmin inhibitor compound antibody, and the reagent R2 comprises an acridinium ester labeled plasmin-alpha 2 plasmin inhibitor compound antibody; the calibrator is prepared from a plasmin-alpha 2 plasmin inhibitor compound; and the quality control product comprises a plasmin-alpha 2 plasmin inhibitor compound. According to the invention, the accuracy of the detection result of the plasmin-alpha 2 plasmin inhibitor compound can be improved.

The invention provides a method for detecting plasmin in dairy products, which comprises the following steps: firstly dissociating plasmin in milk in a buffer solution (containing a dissociating agent), and then hydrolyzing non-fluorescent coumarin peptide by using the dissociated plasmin to release 7-amino-4-methyl coumarin (AMC). And determining the activity of plasmin in the sample by measuring the concentration change of the fluorescence product AMC. According to the present invention, the dissociation reagent, the detection mode (dynamic and non-dynamic), the detection instrument parameter, the specific detection process and the like are subjected to the experimental invention improvement, and the detection method suitable for the experimental matrix is established so as to provide the more accurate detection data; results show that the standard curve obtained by the method is excellent in linearity and relatively good in repeatability, and the detection result is not influenced by the milk turbidity and is stable.

The invention relates to a plasmin inhibitor as well as a preparation method and application thereof, in particular to a compound which can inhibit plasmin activity and delay fibrinolysis, has blood coagulation and hemostasis activity and is shown in a formula (I), pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures thereof, and X, R1 to R5 are defined in the specification.

The invention discloses a fermented soybean fermentation process for high-yield plasmin and thrombolysis application thereof. According to the method, black beans are used as raw materials, water is added for soaking and sterilization, bacillus subtilis is added, the mixture is put into a constant-temperature and constant-humidity incubator for fermentation, according to plasmin activity, the fermentation temperature, humidity, time, inoculation amount, loading capacity and solid-liquid ratio are subjected to a single-factor test, the solid-state fermentation conditions are optimized, and the plasmin solid-state fermentation effect is improved. An optimal solid-state fermentation process is determined by combining an orthogonal test, high-plasmin-yield fermented soybean is obtained through an ultralow-temperature freeze-drying technology, and finally, the safety and thrombolysis effect of the plasmin of the fermented soybean are verified through in-vivo and in-vitro thrombolysis experiments. Compared with the traditional processing process, the fermented soybean processed by the method disclosed by the invention has the advantages that the influence of seasonal and environmental conditions is reduced by utilizing the principle of pure fermentation, the quality stability of the fermented soybean is improved, and meanwhile, the production of the fermented soybean with high plasmin yield lays a foundation for the development of thrombolytic drugs.

This invention belongs to the field of biomedicine and relates to a procoagulant polypeptide TPTX and its applications. The procoagulant polypeptide TPTX of this invention can exert its procoagulant and hemostatic effects by specifically inhibiting plasmin activity. Experiments have shown that TPTX exhibits significant dose-dependent procoagulant and hemostatic effects in ferric chloride-induced mouse carotid artery thrombosis models, mouse liver hemorrhage models, mouse tail hemorrhage models, and mouse saphenous vein hemorrhage models, with effects superior to the positive control drug 6-aminocaproic acid. Simultaneously, TPTX can reduce the area of ​​atorvastatin-induced cerebral hemorrhage in zebrafish and improve their motor dysfunction. Mechanistic studies show that TPTX has an inhibitory constant Ki of 17.76 nM on plasmin and has no significant effect on the activity of seven other key serine proteases in the coagulation system, demonstrating a clear target and high selectivity. The procoagulant polypeptide of this invention can be used to prepare hemostatic drugs, possessing the advantages of high efficiency, clear target, and high selectivity, with broad prospects for clinical application.

The present invention discloses a plasmin-inhibiting peptide YHX-PIP-4 derived from bovine milk protein and its application, and relates to the technical field of bioactive peptides. The present invention provides a plasmin-inhibiting peptide YHX-PIP-4 derived from β-lactoglobulin, whose amino acid sequence is shown in SEQ ID NO.1. With the help of bioinformatics technology, the present invention screened a peptide segment with plasmin inhibition ability from the β-lactoglobulin sequence through molecular docking and molecular dynamics simulation technology. This peptide segment is named plasmin-inhibiting peptide YHX-PIP-4; studies have confirmed that the plasmin-inhibiting peptide YHX-PIP-4 can inhibit the activity of plasmin, and adding it to ultra-high temperature milk can avoid the precipitation and aging gel phenomenon of milk during storage, thereby extending its shelf life.

It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU / mg of defibrotide, preferably from 27 to 32 IU / mg and, more preferably, from 28 to 32 IU / mg.

This invention belongs to the field of bioactive peptide technology, and relates to a plasmin inhibitory peptide derived from β-lactoglobulin, its screening method, and its application. Its amino acid sequence is shown in SEQ ID NO.1. This invention selects β-lactoglobulin from bovine milk as the source of the plasmin inhibitory peptide. Using the structure of the naturally conformated μ-plasmin as a template, molecular docking is performed between β-lactoglobulin and plasmin. Molecular dynamics simulations are conducted on the complex until equilibrium is reached. Based on the interaction between the active site of plasmin and the β-lactoglobulin sequence, targeted screening is performed on polypeptide sequences within the β-lactoglobulin sequence that may have inhibitory activity, resulting in a small, short peptide that specifically inhibits plasmin and can be rapidly synthesized artificially. Adding this plasmin inhibitory peptide to UHT milk increases the stability of sterilized milk and extends its shelf life, showing promising application prospects.

The present disclosure provides combinations of tissue plasminogen activator mutant / s and lysine analogs and compositions thereof for inhibiting fibrinolysis induced by free plasmin. The present disclosure further provides kits, uses and methods for treating coagulopathy associated with anti-fibrinolytic therapy.

The present invention relates to a method for isolating and culturing tissue-resident uPAR+ / Nestin+ stem cells, and a use thereof, and provides a method for isolating, on the basis of uPAR-plasmin activity, tissue-resident stem cells present in solid tissues, wherein the uPAR-plasmin activity of stem cells has been suggested to have a close relationship with stem cell growth, migration ability, physiological activity and differentiation ability, and thus can be used in a method for isolating high-potency stem cells, the uPAR+ stem cells isolated from solid tissues are applicable to the production of cell therapeutic agents, tissue engineering therapeutic agents, and novel biopharmaceuticals using secretions including exosomes, and thus have high industrial applicability, and the present invention is applicable to fundamental cell biology and molecular biology research and novel drug development research that relate to the cell division, migration, growth, and differentiation of tissue-resident stem cells.

The present disclosure provides compositions for use in a hemostasis blood test, as well as related methods, systems, kits, and sample holders. The compositions include any one or more of (a) a plurality of phospholipids, (b) a plurality of activators, (c) a blood coagulation initiator, and (d) plasmin or a precursor thereof. In some embodiments, the compositions further include one or more of (e) a buffering agent, (f) a sugar, (g) a protein concentration reference standard, and (h) CaCl2.

The invention belongs to the technical field of dairy product processing, and discloses a buffalo formula milk quality monitoring method. According to the method, the raw material key indexes and the whole-flow process data of the buffalo formula milk are obtained in real time through the online sensor network, second-level calculation is carried out by utilizing the special dynamic model, and the plasmin activity of the buffalo formula milk can be predicted in real time before product packaging is completed. According to the method, quality control is converted from finished product sampling inspection depending on lag to process prediction based on real-time data for the first time, and real preventive quality control is achieved. According to the method, through source risk instant grading and production process real-time deviation correction, disqualification of the whole batch of products caused by high-risk raw materials or process deviation can be effectively prevented, and the quality loss is greatly reduced. And meanwhile, the dependence on frequent and destructive off-line sampling inspection is reduced, and the detection cost and time are saved.

The present invention provides engineered plasmin variants and related compositions that are resistant to inhibition of plasmin protease activities by plasmin inhibitors, which can be used as direct-acting thrombolytic agents in the treatment of thrombosis and thrombotic disorders.

The present application relates to the technical field of in vitro diagnosis, in particular to plasmin-alpha2 plasmin inhibitor complex determination reagent and application thereof.The present application provides plasmin-alpha2 plasmin inhibitor complex determination reagent, which comprises magnetic particle suspension and labeled antibody mixture.The magnetic particle suspension comprises plasmin-alpha2 plasmin inhibitor complex antibody coated magnetic particles and magnetic particle buffer.The labeled antibody mixture comprises tracer labeled plasmin-alpha2 plasmin inhibitor complex antibody and labeled antibody buffer.The magnetic particle buffer and the labeled antibody buffer comprise buffer system, stabilizer and preservative.The reagent combination provided by the present application has high accuracy and good repeatability, and is suitable for popularization and application.

This invention belongs to the field of bioactive peptide technology, and relates to a β-lactoglobulin-derived plasmin inhibitory peptide, its screening method, and its application. The amino acid sequence of the plasmin inhibitory peptide is shown in SEQ ID NO.1. The screening method involves selecting β-lactoglobulin from bovine milk as the source of the plasmin inhibitory peptide. After preliminary verification that β-lactoglobulin has the ability to inhibit plasmin, molecular docking is performed on β-lactoglobulin and plasmin. The complex is then subjected to molecular dynamics simulation to equilibrium. Based on the interaction between the active site of plasmin and the β-lactoglobulin sequence, targeted screening is conducted on polypeptide sequences in the β-lactoglobulin sequence that may have inhibitory activity. This method solves the technical defects in the current preparation process of plasmin inhibitory peptides, such as the scarcity of raw materials, complex processes, and difficulty in large-scale production. This plasmin inhibitory peptide increases the stability of sterilized milk and extends its shelf life, showing good application prospects.

The invention discloses an anti-PIC monoclonal antibody as well as a coding sequence and application thereof, the antibody or an antigen binding fragment thereof can be specifically bound with a compound of an alpha2-plasmin inhibitor and plasmin, and the antibody or the antigen binding fragment thereof comprises heavy chain variable regions CDR-H1, CDR-H2 and CDR-H3 and light chain variable regions CDR-L1, CDR-L2 and CDR-L3. The antibody or the antigen binding fragment thereof can be specifically bound with a compound of an alpha2-plasmin inhibitor and plasmin, can be used for preparing a chemiluminescent reagent and quantitative detection of PIC, has the detection sensitivity of 0.05 mu g / mL, has high correlation with a measured value of a clinical plasma sample, has a correlation coefficient R2 of more than or equal to 0.950, and meets the requirements of clinical detection.

It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU / mg of defibrotide, preferably from 27 to 32 IU / mg and, more preferably, from 28 to 32 IU / mg.